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Persistent throat symptoms, such as throat clearing, globus sensation, voice change and catarrh are 
extremely common. On very limited evidence, they are increasingly attributed to “laryngopharyngeal 
reflux (LPR)” and treated with proton pump inhibitors (PPIs) in primary and secondary care.  
Methods 
A double blind placebo controlled UK multicentre phase III trial randomly allocated adults with persistent 
throat symptoms 1:1 to either 30 mg of Lansoprazole or matched placebo twice daily for 16 weeks, 
stratified by centre and symptom severity. The primary outcome was patient-reported symptomatic 
response, measured by the total Reflux Symptom Index (RSI) score at the end of therapy. Secondary 
outcomes included safety, further symptoms and quality of life measures at 12-months. 
Results  
346 participants were randomised from 8 UK centres: mean (sd) age 52 (13), 196 (57%) female, 162 
(47%) severe symptoms, balanced across randomised groups. Mean RSI scores (95% CI) were similar at 
baseline- Lansoprazole: 22.0 (20.4, 23.6), placebo: 21.7 (20.5, 23.0). Improvements (reduction in score) 
were observed in both groups at 16-weeks: Lansoprazole: 17.4 (15.5, 19.4), placebo: 15.6 (13.8, 17.3) 
(p=0.096 adjusted by site, severity). There was no statistically significant difference between randomised 
groups.  No significant differences were observed in the secondary outcome measures.  
Conclusions 
TOPPITS is the largest, definitive trial to assess PPI effectiveness for persistent throat symptoms. It found 
no advantage of Lansoprazole over placebo in a range of outcomes. The near routine use of PPIs for 












Persistent throat symptoms incorporate various common complaints that include: hoarseness, a feeling of a 
lump in the throat (“globus”), repeated throat clearing, mucus in the throat or “catarrh”, cough and throat 
discomfort. These are a burden to health care providers. The prevalence of globus alone, in middle aged 
women, is approximately 6%1 with a lifetime ever population incidence over 40%2. A quarter of all patients 
attending primary care may report significant  throat symptom 3. Many ultimately attend for specialist 
review in secondary care4.  
Gastroesophageal reflux disease (GERD) affects up to 20% of the Western population and the concept that 
GERD causes throat and voice symptoms - “laryngopharyngeal reflux” or “LPR” has been increasingly 
popular for many years 5. A survey in 2007 showed that 90% of British otolaryngologists believed in the 
LPR concept, for which over 50% prescribed proton pump inhibitors (PPIs)6. Large observational cohort 
studies point to symptomatic and endoscopic benefit from PPI treatment 7,8. Meta-analyses of 
heterogeneous, generally underpowered clinical trials have failed to demonstrate any benefit over 
placebo9,10, yet PPIs continue to be the default first line therapy in primary and secondary care. 
The Trial of Proton Pump Inhibitors in Throat Symptoms (TOPPITS) aimed to generate definitive evidence 
on the role of PPIs in the treatment of persistent adult throat symptoms.  
Methods 
Oversight of the trial 
TOPPITS was an investigator-initiated multicentre, randomised, double-blind, placebo controlled trial 
conducted in 8 hospitals in the United Kingdom. The trial protocol was approved by the regional ethics 
committee and has been published previously11. The trial was independently funded by the Health 
Technology Assessment (HTA) peer review programme of the National Institute for Health Research.  
Both an independent Data Monitoring Committee (DMC) and Trials Steering Committee (TSC) provided 
oversight of the trial. TOPPITS was performed in accordance with the principles of the Declaration of 
Helsinki. The authors take responsibility for the fidelity of the trial and the accuracy and completeness of 




Participants were adult patients, newly referred to secondary care otolaryngology clinics with persistent 
(over six weeks) unexplained throat symptoms, principally: hoarseness, throat pain, globus sensation, 
throat clearing, post nasal drip or mucus excess, night time unexplained cough or choking. These 
symptoms were assessed using the Reflux Symptom Index (RSI) patient self-report questionnaire12, a 
score commonly utilised and supported with published sensitivity data. However, item nine of the RSI is 
a composite GERD question covering heartburn (HB), chest pain, indigestion or stomach acid coming up. 
Item nine was therefore omitted from our eligibility assessment and from baseline stratification, which 
aimed to balance throat symptom severity between the groups. To be eligible for TOPPITS, patients 
required a score of 10 or more on the remaining 8 items of the RSI (which we term RSI-HB). Patients 
were excluded if laryngopharyngeal endoscopy revealed pathology requiring specific treatment, such as 
vocal cord polyps or malignancy, or if they had a contraindication to receive proton-pump inhibitors 
(PPIs). Patients currently taking a PPI required a wash-out period of 4 weeks to enter the trial and those 
taking alginates were required to discontinue these. The complete list of inclusion and exclusion criteria 
has been published previously11.  All participants provided written informed consent. 
Trial Procedures 
The active intervention was a 16-week course of a 30mg twice-daily dose of the PPI Lansoprazole, taken 
30 minutes before food.  The control group received a 16-week course of twice-daily matched placebo 
capsules. The allocation was blind to participant and research team staff (double-blind) and was 
maintained through the trial. A blocked allocation randomisation system (permuted random blocks of 
variable length) was developed by an independent statistician and used to allocate patients in a 1:1 ratio 
stratified by centre and baseline severity on the basis of a dichotomised RSI-HB score (10 ≤ Mild ≤ 20; 
Severe > 20). The TOPPITS severity strata were derived from data in prior published RSI datasets  7,8,13,14. 
Randomisation was administered centrally via the Newcastle Clinical Trials Unit using a secure web-




The primary outcome measure was the total RSI score at 16 weeks after randomisation12. The RSI score is 
a summation of all nine-items, scored on a 6 point Likert scale 0-5, giving a total RSI range of 0-45 (see 
Supplementary Appendix). A higher score indicates more severe symptoms.  
The secondary outcome measures were:  
• Adverse events 
• Compliance with intervention 
• RSI at 12 months from randomisation 
• RSI score omitting the GERD item (RSI-HB) (score 0 to 40) 
• Two further patient self-report symptom measures, the 34 item Comprehensive Reflux Symptom 
Score13 and the 43 item Laryngopharyngeal Health Related Quality of Life (LPR HRQL) within 
12-months14. For both, higher scores equate to more severe symptoms 
• Utility of baseline laryngeal mucosal changes (assessed by a single clinician, blind to the 
symptom scores) recorded by the Reflux Finding Score (RFS) 15 as a predictor of outcome 
• Patient post treatment prediction of allocated intervention 
Statistical Considerations 
The primary analysis of the primary outcome measure was a multivariable multilevel mixed effect linear 
regression to compare the RSI at 16 weeks while adjusting for the stratification factors at randomisation: 
i) centre, as a random effect, and ii) the mild / severe  baseline severity as a fixed effect. The primary 
intention to treat analysis (ITT) was performed on a “compliant” group of patients, as defined by the TSC 
i.e. those who completed the primary outcome within a 14 to 20 week window, retaining patients in their 
randomised group. Secondary ITT analyses were performed on the “pragmatic” group i.e. all patients 
completing the primary outcome. Secondary analyses of the primary outcome also included adjustment 
for RFS as a continuous measure (investigating non-linear relationships using first order fractional 
polynomial transformation) and for other important clinical and demographic baseline factors.   
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Analyses of secondary outcomes followed a similar strategy for questionnaire scores. Safety data were 
not subject to statistical comparison. Data were analysed using statistical software package (STATA14). 
A Statistical Analysis Plan, following published guidance16 was in place prior to comparative analyses. 
No formal interim analyses were planned.   
Target recruitment was 332 patients. A mean difference of 3-points in RSI score at 16 weeks was deemed 
to be clinically relevant. With an assumed standard deviation of 7.717 a mean difference of 3.1 points 
equates to a  standardised mean effect size of 0.4. A total of 332 participants (166 in each arm of the 
study) were estimated to provide 266 participants (133 in each arm) completing the trial intervention, to 




A total of 346 patients, from 1427 initially screened for eligibility, were recruited through 8 UK centres 
and randomised between April 2014 and February 2017; 172 to Lansoprazole and 174 to placebo (Figure 
1). Drop-out was observed as anticipated in the design and was not differential across randomised groups. 
There were 267 (77%) patients who completed the primary outcome measure at 16 weeks (pragmatic ITT 
group), 220 within the 14 to 20 week window (compliant ITT group). RSI questionnaires returned at 16-
weeks were fully completed.  The power to detect the clinically relevant difference in RSI score at 16 
weeks was 82% (compliant group) and 89% (pragmatic group).  
The compliant ITT group were a representative sample of the trial population in terms of demographics 
(Table 1): 126 (57%) were female, mean (sd) age 54.5 (13.1), 107 (49%) severe RSI-HB and overall 
mean (sd) RSI-HB score of 20.0 (7.0), balanced across randomised arms (see Supplementary Appendix 





In total, 265 of 346 (77%) had information on returned trial medication of whom 262 (99%) were 
reported to have started treatment, taking at least one capsule. Treatment kits contained a 16-week course 
of 224 capsules.  111  (42%) of patients reported taking full dose, balanced across randomised groups, 
while 184 (70%) patients reported taking at least 90% of full dose, balanced across randomised groups.  
There were 112 adverse events (AE) reported in 74 patients, 80 (71%) of which occurred during 
treatment: 42 (70%) Lansoprazole and 38 (73%) placebo. One severe AE was probably related to 
treatment; a rash appearing after taking the allocated treatment. 
When asked, post treatment, to predict their allocated intervention, 42% of the Lansoprazole group and 
56% of the placebo correctly identified the treatment they had received at the end of the trial period, hence 
the blinding was maintained. 
 
Primary Outcome Measure 
An improvement in RSI (reduction in score) was observed overall in the compliant ITT group at 16 
weeks, reducing from mean 21.9 (sd 7.5) at baseline to mean 16.4 (sd 9.9). This improvement was 
observed in both randomised treatment groups (Table 2, Figure 2). Multilevel mixed effect linear 
regression of 16-week RSI, adjusted for stratification factors at randomisation (site and RSI-HB severity 
category) showed baseline RSI-HB to be significantly related to 16-week RSI (Table 3). Patients in the 
severe severity stratum at baseline are estimated to have eight points higher (worse) RSI score at 16 
weeks. There was no statistically significant difference in RSI scores at 16-weeks between randomised 
groups: Lansoprazole patients are estimated to have scores 1.9 points higher (worse) than placebo (95% 
CI: -0.3, 4.2, p=0.096) when adjusted for stratification factors. 
 
Secondary analyses of the primary outcome i) in the wider pragmatic ITT group (Supplementary 
Appendix) ii) when adjusting for other important clinical and demographic baseline factors and iii) 
analysing RFS as a continuous measure gave similar results with no statistically significant difference in 
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16 week RSI between the treatment groups, and did not alter the conclusions of the trial. Longer term, the 
trial concluded that Lansoprazole patients were estimated to have RSI scores at 12 months 2.5 points 
higher (worse) than placebo (95% CI: -0.1, 5.0, p=0.06, Supplementary Appendix) 
 
Secondary Outcome Measures 
Analysis of the RSI-HB demonstrated the Lansoprazole group to have a mean 16-week score 2.4 points 
higher (worse) than the placebo group: 16.3 (95% CI: 14.5, 18.1) vs 13.9 (95% CI: 12.2, 15.5). The 
overlapping confidence intervals indicate no statistically significant difference. 
The CReSS scores improve (reduce) from baseline to 16 weeks in both randomised treatment groups (see 
Supplementary Appendix) with overlapping confidence intervals.  
The mean LPR HRQL quality of life scores show similar marked improvement at 16-weeks in both 
randomised treatment groups (see Supplementary Appendix).  Multi-level modelling estimated 
Lansoprazole has on average 2.9 higher (worse) overall LPR HRQL outcome score than placebo (95% 
CI: -4.3, 10.1, p=0.427).   
Reflux Finding Scores at baseline were available for 256 patients in the trial (80% of those in the 
Lansoprazole arm and 72% in the placebo arm). Mean baseline RFS scores (sd) were 9.7 (4.1) in the 
Lansoprazole group and 9.2 (3.8) in the placebo group. The baseline RFS scores were not significantly 
related to the RSI score at 16 weeks using first order fractional polynomial transformations. 
 
Discussion 
The TOPPITS trial is the largest, fully powered, double-blind randomised controlled trial to provide 
definitive evidence of the role of PPIs in treating persistent throat symptoms.  In line with the Health 
Technology and Assessment programme, TOPPITS was a pragmatic design ensuring results are 
immediately generalizable to the clinical setting. The results demonstrate that Lansoprazole offers no 
benefit over placebo for patients with persistent throat symptoms. No trends exist in favour of 
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Lansoprazole. Indeed, patients who received Lansoprazole tended to report worse symptom improvement 
than those receiving placebo. Treating patients “empirically” with PPIs, in the absence of specialist 
investigations, represents by far the commonest current scenario for health care practitioners 
internationally. This practice should now be discouraged through evidence based treatment guidelines.  
Prior high quality evidence is lacking in support of PPIs to treat symptoms. The inability of placebo 
controlled trials to replicate the benefits of PPIs in uncontrolled observational studies of PPIs point to a 
misattribution of placebo enhanced spontaneous resolution in such single cohort reports7,8.A systematic 
review 9 of studies that used PPIs as an empiric treatment modality for suspected LPR identified 14 
uncontrolled studies, one un-blinded, non-randomised study with a control group of healthy volunteers 
and six double-blind, placebo-controlled randomised trials from 1994 to 2004. A lack of common 
outcome measures, selection bias and or inadequate blinding of the results were among typical 
limitations. A later meta-analysis 18 included further studies, notably that of Vaezi et al , and concluded 
that PPI therapy ‘may offer a modest but non-significant clinical benefit’ over placebo. Subsequent meta-
analyses again showed PPI therapy lacked evidence of efficacy in those suspected of LPR. Rather, high 
placebo response levels suggested a much more complex and multifactorial pathophysiology 10,19. Very 
little evidence exists assessing the role of other factors which may reduce reflux, such as diet20, alginates17 
and lifestyle21. The TOPPITS results would support the reinvestment of research into the psychological 
concomitants of throat symptoms; anxiety, distress, depression and co-existing persistent physical 
symptoms22-24. 
TOPPITS demonstrates definitively that Lansoprazole does not benefit patients with persistent throat 
symptoms, over placebo. These findings reasonably extrapolate to other PPIs. TOPPITS does not refute 
reflux as a cause or contributing factor for some patients’ symptoms but the results must surely call into 
question the now near ubiquitous use of the term “laryngopharyngeal reflux”, which has gradually 
supplanted many other terms such as globus and catarrh, and carries unwarranted etiological connotation. 
The authors would advocate the non-prejudicial term “persistent throat symptoms” to promote further 
research into optimum management strategies of these complaints. Whilst reflux of gastric contents 
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containing pepsin may be implicated in some patients, defining such individuals requires further research. 
It is probable that reflux does not play a significant role for the vast majority of patients with persistent 
throat symptoms. Strategies that employ the techniques of reattribution, lifestyle adjustment and 
behaviour modification of speech or cognitive behavioural therapy 24-28 appear more relevant and a 
reasonable focus of further research.  
Conclusions 
Twice daily Lansoprazole offered no symptomatic benefit over matched placebo for patients with 
persistent throat symptoms. The TOPPITS trial is the largest double-blind, multi-centre randomised 
controlled trial to date and confirms that the common practice of prescribing PPIs to this patient 
population should be discontinued.  
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Table 1 Baseline demographic data 
  All Patients  Compliant ITT group  












Gender                                    
 














Age(years)                     
 












54.5 (13.1)                                                     
(21, 84) 
Body Mass Index                               
 












28.5 (6.1)                                                     
(11.3,56.9) 
Baseline severity RSI-HB 
   
































































Assessed for eligibility (n=1427) 
Excluded (n=1081) 
♦   Ineligible (n=558) 
♦   Declined to participate (n=404) 
♦   Other reasons (n=119) 
Pragmatic ITT (n=127) 
Compliant ITT (n=102) 
Attended 16 week visit (n=135) 
-withdrew (n=31) 
-Did not attend 16 week visit (n=6) 
-Primary outcome completed (n=127) 
 
Allocated to Lansoprazole (n=172) 
♦ Received allocated intervention (n=172) 
♦ Did not receive allocated intervention (n=0) 
   
 
Attended 16 week visit (n=148) 
-withdrew (n=23) 
-Did not attend 16 week visit (n=3) 
-Primary outcome completed (n=140) 
 
 
Allocated to Placebo (n=174) 
♦ Received allocated intervention (n=172) 
♦ Did not receive allocated intervention (n=2) 
  − Ineligible - no medication assigned withdrew (n=1) 




Pragmatic ITT (n=140) 




baseline visit (v1) 
Primary Analysis. 
 
Primary endpoint visit 




Attended 12 month follow up visit (n=109)  
-Did not attend 12 month visit (n=2) 
-withdrew =63 
  (2 of 63 withdrew from IMP & attended visit)  
- Pragmatic ITT (n=109) 




Attended 12 month follow up visit (n=117) 
-Did not attend 12 month visit (n=2) 
-withdrew =62 
  (7 of 62 withdrew from IMP & attended visit)  
- Pragmatic ITT =117 




Final follow up visit 






Table 2 Summary of questionnaire outcome scores [mean (95% Confidence Interval)] 
   Visit 





22.0 (20.4, 23.6) 
21.7 (20.5, 23.0) 
17.4 (15.5, 19.4) 
15.6 (13.8, 17.3) 
16.0 (13.6, 18.4) 





20.3 (18.8, 21.7) 
19.8 (18.6, 21.0) 
16.3 (14.5, 18.1) 
13.9 (12.2, 15.5) 
13.5 (6.0, 22.0) 





50.3 (44.9, 55.7) 
51.1 (46.4 ,55.8) 
38.9 (33.4, 44.3) 
34.7 (29.6, 39.9) 
36.6 (29.8, 43.5) 





28.9 (24.5, 33.3) 
26.5 (22.5, 30.5) 
20.5 (16.1, 25.0) 
17.1 (13.3, 21.0) 
18.8 (13.7, 23.8) 





Figure 2  Reflux Symptom Index score at baseline and follow-up visits (median, interquartile range 









RSI score at baseline RSI score at 16 weeks
RSI score at 12 months
n=102         n=102        n=82                   n=118          n=118         n=99
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Table 3 Multilevel mixed effect linear regression  







95% CI (β) 
lower upper 
Group (ref = Placebo)  
Lansoprazole  
1.929 1.160 1.66 0.096 -0.345 4.203 
RSI-HB baseline severity: (ref =Mild) 
Severe 
8.173 1.181 6.92 <0.001 5.858 10.489 
Constant 14.349 3.044 4.71 <0.001 8.383 20.315 
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Table 1 The Reflux Symptom Index  
 
Permission to use in the trial and reproduce for publication obtained from the authors. The use of the 
Reflux Symptom Index (RSI) without the 9th item (RSI- Heartburn score, RSI-HB) was devised 
specifically for TOPPITS. 
 
Within the last MONTH, how did the following problems affect you?       
0 = no problem   5 = severe problem 
 
Heartburn, indigestion or stomach acid 
coming up 
0 1 2 3 4 5 
 




Hoarseness or a problem with your voice 0 1 2 3 4 5 
Clearing your throat 0 1 2 3 4 5 
Excess throat mucus or postnasal drip 0 1 2 3 4 5 
Difficulty swallowing food, liquids or tablets 0 1 2 3 4 5 
Coughing after eating or lying down 0 1 2 3 4 5 
Breathing difficulties or choking episodes 0 1 2 3 4 5 
Troublesome or annoying cough 0 1 2 3 4 5 
Sensation of something caught in your 
throat or a lump in your throat 




Table 2 Baseline demographic characteristics and stratification variables, all randomised patients and pragmatic ITT population  
 All randomised patients (n=346) Pragmatic ITT population  (n=267) 
Variable Lansoprazole Placebo Total Lansoprazole Placebo Total 
Gender                               Male 













Age(years)                 Mean (SD)      













Body Mass Index (BMI)          n 
                                 Mean (SD) 







339                                 











Baseline severity RSI-HB        n                                                       
                                  Mean (SD) 



















*Severity                    Mild 


















T a bl e 3 Pri m ar y o ut c o m e m e as ur e R SI , pr a g m ati c I T T p o p ul ati o n 
 B as eli n e ( Vi sit  1)  1 6 w e e ks ( Vi sit 2)  
L a ns o pr a z ol e  
( N = 1 2 7) 
Pl a c e b o  
( N = 1 4 0) 
L a ns o pr a z ol e  
( N = 1 2 7) 
Pl a c e b o  
( N = 1 4 0) 
M e di a n (I Q R)  2 1 ( 1 6, 2 6)  2 2 ( 1 6, 2 7)  1 5 ( 9, 2 5)   1 5 ( 8, 2 3)  
M e a n ( S D) ; CI                                                   2 1. 7 ( 7. 4)  2 1. 9 ( 7. 0) 1 7. 1 ( 9. 6) ; 1 5. 5, 1 8. 8 1 6. 0 ( 9. 5) ; 1 4. 4, 1 7. 6 
R a n g e  ( 1 0, 4 1) ( 1 0, 4 3) ( 0, 4 1) ( 0, 4 4) 
CI = 9 5 % c o nfi d e n c e i nt er n al a b o ut m e a n  
 
T a bl e 4 M ultil e v el mi x e d eff e ct li n e ar r e gr essi o n , pr a g m ati c I T T p o p ul ati o n 
M o d el ( n = 2 6 7 ) * β 
 
s e (β ) 
 
T est 
st atisti c 
p- v al u e  
9 5 % CI (  ) 
l o w er u p p er  
Gr o u p (r ef = Pl a c e b o)  
L a ns o pr a z ol e   
1. 4 6 5 1. 0 5 6 1. 3 9 0. 1 6 5 - 0. 6 0 4 3. 5 3 4 
R SI -H B b as eli n e s e v erit y: (r ef = Mil d)  
S e v er e  
7. 4 4 4 1. 0 7 1 6. 9 5 < 0. 0 0 1 5. 3 4 5 9. 5 4 3 
C o nst a nt  1 5. 1 7 4  3. 0 1 4  5. 0 3  < 0. 0 0 1  9. 2 6 7  2 1. 0 8 1  
* A dj ust e d b y Sit e ( R a n d o m Eff e ct); s e =st a n d ar d err or; CI = c o nfi d e n c e i nt er v al 
 
 
T a bl e 5 M ultil e v el mi x e d eff e ct li n e ar r e gr essi o n  at 1 2 m o nt hs, c o m pli a nt I T T p o p ul ati o n 
M o d el ( n = 1 8 5) * β  
 
s e (β ) 
 
T est 
st atisti c 
p- v al u e  
9 5 % C I (β ) 
l o w er u p p er  
Gr o u p  (r ef =  Pl a c e b o)  
L a ns o pr a z ol e   
2. 4 6 9 1. 3 1 1 1. 8 8 0. 0 6 0 - 0. 1 0 0 5. 0 3 8 
R SI -H B b as eli n e s e v erit y : (r ef = M il d) 
S e v er e  
8. 2 3 3 1. 3 1 4 6. 2 7 < 0. 0 0 1 5. 6 5 8 1 0. 8 0 8 






Table 6 Comprehensive Reflux Symptom Score total scores at 16 weeks 
CReSS Total (range: 0-170) 
Lansoprazole Placebo  
n  102  118  
Median (LQ, UQ) 36 (15,55) 27.5 (14,48) 
Mean (SD)                                                   38.9 (27.7) 34.7 (28.3) 
95% CI (33.4, 44.3) (29.6, 39.9) 
Range (min, max) (2,140) (0,158) 
 
 





































mean 95% confidence interval
n=99    n=100                            n=79     n=115       n=117                        n=97
Scale range: 14-140
